Shorter-term dual antiplatelet therapy after receiving drug-releasing stent does not worsen outcomes

Short-term (3 months) vs. long-term (12 months) dual anti­platelet therapy did not result in poorer outcomes on certain measures (death, heart attack, stroke, and bleeding) for patients with coronary artery disease or low-risk acute coronary syndromes (such as heart attack or unstable angina) treated with drug (zotarolimus)-releasing stents, according to a study published by JAMA. The study is being published early online to coincide with its presentation at the Transcatheter Cardiovascular Therapeutics 25th annual meeting...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Heart Disease Source Type: news